Jacobs Levy Equity Management
NGM

Jacobs Levy Equity Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Jacobs Levy Equity Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-555,826
Closed -$477K – 1085
2023
Q4 		$477K Sell
555,826
-2,778
-0.5% -$2.44K ﹤0.01% 837
2023
Q3 		$598K Sell
558,604
-20,282
-4% -$42K ﹤0.01% 766
2023
Q2 		$1.5M Sell
578,886
-164,353
-22% -$586K 0.01% 624
2023
Q1 		$3.03M Buy
743,239
+70,075
+10% +$324K 0.02% 491
2022
Q4 		$3.38M Buy
673,164
+604,515
+881% +$3.79M 0.02% 463
2022
Q3 		$898K Buy
+68,649
New +$1.04M 0.01% 730
2022
Q2 		– Sell
-351,943
Closed -$5.37M – 1114
2022
Q1 		$5.37M Sell
351,943
-76,483
-18% -$1.19M 0.04% 402
2021
Q4 		$7.59M Sell
428,426
-29,520
-6% -$566K 0.05% 353
2021
Q3 		$9.63M Buy
457,946
+205,123
+81% +$4.52M 0.06% 302
2021
Q2 		$4.99M Buy
252,823
+22,351
+10% +$523K 0.03% 430
2021
Q1 		$6.7M Buy
230,472
+12,266
+6% +$343K 0.05% 372
2020
Q4 		$6.61M Sell
218,206
-10,624
-5% -$232K 0.06% 342
2020
Q3 		$3.64M Buy
228,830
+29,434
+15% +$537K 0.04% 410
2020
Q2 		$3.94M Buy
199,396
+61,432
+45% +$1.17M 0.04% 390
2020
Q1 		$1.7M Buy
+137,964
New +$2.25M 0.02% 513

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management's NGM Position: Q1 2024 in Review

Jacobs Levy Equity Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 555,826 shares — an estimated $477K sold.

Jacobs Levy Equity Management first reported a position in NGM in Q1 2020 and held it in 15 quarters. The position peaked at $9.63M in Q3 2021. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Jacobs Levy Equity Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 555,826 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $477K.
  • Jacobs Levy Equity Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 15 quarters.
  • Jacobs Levy Equity Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $9.63M in Q3 2021.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2024, filed 15 May 2024.